

SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad

Sandra Amor^{1,2}, David Baker², Samia J. Khoury^{3,4}, Klaus Schmierer^{2,5}, Gavin Giovanonni^{2,5}

¹Pathology Department, VUmc, Amsterdam UMC, Amsterdam, The Netherlands

²Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom,

³Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA

⁴Abu Haidar Neuroscience Institute, American University of Beirut, Beirut, Lebanon

⁵Department of Neurology, The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.

A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic¹ is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of contracting SARS-CoV-2 and more severe disease. The Society of Italian Neurologists (SIN) and the Association of British Neurologists (ABN) MS and Neuroimmunology Advisory Group published guidance for the use of current disease modifying treatments (DMTs) in MS (Table 1)². However, taking into account, less conservative viewpoints³, the emerging knowledge of the biology of SARS-CoV-2, and in particular the role of the immune mechanisms contributing to the disease, we propose modification of these guidelines since it is not clear that immunosuppression is indeed detrimental in people with MS infected with SARS-CoV-2. We are thus proposing a more nuanced approach and that the categories of DMTs should be modified based on scientific principles and the biology of severe COVID-19 (Table 2).

The immune mechanisms contributing to severe COVID include viral subversion of innate immunity and infection of macrophages⁴, and if similar to SARS CoV, may trigger apoptosis of leucocytes leading to lymphopaenia⁵. The exact mechanisms are as yet unclear but suppression of innate responses due to modulation of IFN production or receptor signalling, and the apoptotic effects of virally encoded proteins have been proposed⁶. Together these allow widespread viral infection, excessive monocyte/macrophage activation and in severe cases a cytokine storm triggering severe acute respiratory distress syndrome (ARDS). The viral specific CD8 T cell responses appear to eliminate SARS-CoV-2 while viral specific antibodies are probably more important to prevent reinfection and create long-lasting immunity. A direct role of B cells in the destructive COVID-19 pathology is unlikely since people with X-linked agammaglobulinemia that recover from the COVID-19 pneumonia and lymphopenia without need of intensive care

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ana.25770

or oxygen ventilation⁷. In MS, although a single case, ocrelizumab treatment did not augment or prolong COVID-19 symptoms⁸.

Since many of the MS DMTs have been designed to target the adaptive immune response; and for therapeutic effect most likely need to target the memory B cells⁹ it is unlikely that MS DMTs treatment impact on the innate immune responses although there is some evidence that fingolimod¹⁰ and alemtuzumab¹¹ impact on the innate immune system. In addition DMTs do not substantially limit the antibody responses to SARS-CoV-2 and thus do not pose a risk in the development of protective neutralising antibody responses although some DMTs will blunt this.

To avoid 'throwing the baby out with the bathwater' we recommend revision of the published guidelines² in light of the role of the immune response in controlling SARS-CoV-2 infection (Table 2), the emerging biology of COVID-19, and accumulating MS cases reports. We propose that while administration of some DMTs should be modified, others may well control the pathogenic immune responses during severe COVID-19. For example, whilst in contrast with the original guidelines suggest anti-CD20 therapies may increase the risk of infection^{12,13} but this does not necessarily imply a greater risk of poor outcomes following infection. In addition, most MS-related DMTs do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19, perhaps with the exception of alemtuzumab¹⁴. Importantly, MS DMTs do not generally block immature B cell development thus allowing antibody production preventing (re)infection, as well as response to vaccines when available. However, we recommend adjustments to dosing schedules to reduce the chance of infection.

Apart from the reactivation of herpes infections, the moderate immunosuppression obtained with most MS DMTs rarely leads to problems dealing with viral infections, even in the case of novel viral infections such as dengue fever¹⁵. With the notable exception of PML and other rare CNS viral infections in natalizumab treated patients, which can be de-risked by adopting extended interval dosing¹⁶, would indicate that the initiation and continuation of DMTs in MS does not pose an additional risk of developing more severe COVID-19 to people with MS. Indeed immunosuppression to COVID-19 has been proposed as a rational therapeutic approach^{17,18}. This hypothesis is currently being tested in several trials to evaluate several immunosuppressive therapies for COVID-19, which include fingolimod, a S1P modulator (NCT04280588) and IFN γ (NCT04343768, NCT04350671) that are already widely used to treat MS. Whilst the information is only emerging we anticipate that knowledge arising from registers collating data on people with MS, DMTs and their responses to SARS-CoV2 infection (e.g. NCT04354519) will support the hypothesis that moderate immunosuppression induced by the DMT used in MS may protect against the development of severe COVID-19 infection, which is contrary to current opinion.

The accumulating real-world data on the susceptibility of pwMS to develop severe COVID-19 being treated with immunosuppressive therapies will allow us to accept or reject this hypothesis.

Author contributions: SA, DB, KS and GG all contributed equally to the literature search and writing and SJK assisted with additional comments and suggestions for the final draft.

Role of the funding source: This study received no funding

Disclosures: No company was involved in the decision to write or was involved in the content of this paper. SA has no COIs. DB received consultancy/speaker fees from: Canbex therapeutics, Inmunebio, Lundbeck, Merck, Novartis, Sanofi Genzyme. KS has received consultancy, speaker fees from: Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. GG has received consultancy, speaker fees or research support from: Abbvie, Actelion, Atara, Biogen, Canbex therapeutics, Celgene, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme, Takeda, Teva. GG has received consultancy, speaker fees or research support from: Abbvie, Actelion, Atara, Biogen, Canbex therapeutics, Celgene, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme, Takeda, Teva and Editor of multiple sclerosis and related disorders.

References

1. WHO. Coronavirus disease 2019 (COVID-19) situation report – 52. March 12, 2020. <https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19>.
2. Coles A, Lim M, Giovannoni G, Anderson P, Dorsey-Campbell, Qualie M. ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic. 2020 2 Apr (https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/02.04.20_ABN_Guidance_on_DMTs_for_MS_and_COVID19_VERSION_4_April_2nd.pdf)
3. Broadley S, Carrol B, Gerbis, Mason D, Boggild M, Beadnall H, van der Walt A, Lechner-Scott J, Frith J, Hodgkinson S, Reddel S, Macdonnell R, Barnett M, Marriott M, McCombe P, Kilpatrick T, Taylor B, Kermode A. Advice for patients with multiple sclerosis and related disorders regarding COVID-19 outbreak. <https://www.msnz.org.nz/wp-content/uploads/2020/04/Alert-Level-4-Advice-for-people-with-MS-9-April-2020.pdf>

4. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, Zhang J, Zhao C. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. *J Med Virol*. 2020b Apr. doi: 10.1002/jmv.25884. [Epub].
5. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, Wu H, Lin Y, Zhang M, Zhang Q, Shi M, Liu Y, Zhou Y, Lan K, Chen Y. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect*. 2020 : 761-770. doi: 10.1080/22221751.2020.1747363.
6. Yang Y, Xiong Z, Zhang S, Yan Y, Nguyen J, Ng B, Lu H, Brendese J, Yang F, Wang H, Yang XF. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. *Biochem J*. 2005 Nov 15; 392(Pt 1): 135-43.
7. Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, Bezzi M, Baronio B, Giacomelli M, Badolato R. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. *Pediatr Allergy Immunol*. 2020 Apr 22. doi: 10.1111/pai.13263.
8. Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, Inglese M: COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? *Mult Scler Relat Disord*. 2020 Apr 15; 42: 102120. doi: 10.1016/j.msard.2020.102120.
9. Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. *EBioMedicine*. 2017; 16: 41-50.
10. Thomas K, Sehr T, Proschmann U, Rodriguez-Leal FA, Haase R, Ziemssen T. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. *J Neuroinflammation*. 2017 14: 41. doi: 10.1186/s12974-017-0817-6.
11. Baker D, Giovannoni G, Schmierer Marked neutropenia : Significant but rare in people with multiple sclerosis after alemtuzumab treatment. *Mult Scler Relat Disord*. 2017 Nov; 18: 181-183. doi: 10.1016/j.msard.2017.09.028. Epub 2017 Sep 25.
12. Hauser, S.L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K.W., Selmaj, K., Traboulsee, A., Wolinsky, J.S., Arnold, D.L., Klingelschmitt, G., Masterman, D., Fontoura, P., Belachew, S., Chin, P., Mairon, N., Garren, H., Kappos, L., OPERA I and OPERA II

Clinical Investigators, 2017. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *N. Engl. J. Med.* 376, 221–234.

13. Montalban, X., Hauser, S.L., Kappos, L., Arnold, D.L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Rammohan, K.W., Selmaj, K., Traboulsee, A., Sauter, A., Masterman, D., Fontoura, P., Belachew, S., Garren, H., Mairon, N., Chin, P., Wolinsky, J.S., ORATORIO Clinical Investigators, 2017. Ocrelizumab versus placebo in primary progressive multiple sclerosis. *N. Engl. J. Med.* 376, 209–220.

14. Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. *JAMA Neurol.* 2017 Aug 1; 74(8):961-969. doi: 10.1001/jamaneurol.2017.0676.

15. Fragoso YD, Gama PD, Gomes S, Khouri JM, Matta AP, Fernanda Mendes M, Stella CR. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab. *Mult Scler Relat Disord.* 2016 Mar; 6: 64-5. doi: 10.1016/j.msard.2016.01.005. Epub 2016 Jan 28.

16. Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM. Extended interval dosing of natalizumab in multiple sclerosis.

16. Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM. Extended interval dosing of natalizumab in multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2016 Aug; 87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25.

17. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS⁵, Manson JJ⁶; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression *Lancet.* 2020 Mar 28; 395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.

18. D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. *Liver Transpl.* 2020. doi: 10.1002/lt.25756.

Table 1. Society of Italian Neurologists (SIN) and the Association of British Neurologists (ABN) guidelines for the DMTs in use for MS during COVID-19 pandemic²

At risk category	Class	Trade Name	Safe to start treatment	On treatment	COVID-19 infection	Mode of action
Low	Interferon-Beta	Betaferon, Avonex, Rebif, Plegridy	Yes	Continue	Stop	Immunomodulatory (not immunosuppressive), pleiotropic immune effects
Low	Glatiramer acetate	Copaxone	Yes	Continue	Stop	Immunomodulatory (not immunosuppressive), pleiotropic immune effects
Low	Teriflunomide	Aubagio	Yes	Continue	Stop	Dihydro-orotate dehydrogenase inhibitor (reduced <i>de novo</i> pyrimidine synthesis), anti-proliferative
Low	Dimethyl fumarate	Tecfidera	Yes	Continue	Stop	Pleiotropic, NRF2 activation, downregulation of $\text{nf}\kappa\beta$
Low	Natalizumab	Tysabri	Yes	Continue	Stop	Anti-VLA4, selective adhesion molecule inhibitor
Low	S1P modulators	Fingolimod (Gilenya)	Yes	Continue	Stop	Selective S1P modulator, prevents egress of lymphocytes from lymph nodes
Intermediate	Anti-CD20	Ocrelizumab (Ocrevus)	No (Yes)	Suspend	Delay	Anti-CD20, B-cell depleter
High*	Cladribine	Mavenclad	No	Suspend	Delay	Deoxyadenosine (purine) analogue, adenosine deaminase inhibitor, selective T & B cell depletion
High*	Alemtuzumab	Lemtrada	No	Suspend	Delay	Anti-CD52, non-selective immune depleter
High*	HSCT	-	No	-	Delay	Non-selective immune depleter

*risk refers to acquiring infection during the immunodepletion phase. Postimmune reconstitution the risk is low. Modified from Coles et al 2020²

Table 2. Proposed revised guidelines

At risk category	Class	Trade Name	Safe to start treatment	Advice regarding treatment	COVID-19 infection
Very low	Interferon-beta	Betaferon, Avonex, Rebif, Plegridy	Yes	Continue	Continue
Very low	Glatiramer acetate	Copaxone	Yes	Continue	Continue
Very low	Cladribine/ Alemtuzumab / Mitoxantrone / HSCT	see below	N/A	N/A	N/A
Very low	Teriflunomide	Aubagio	Yes	Continue	Continue
Low	Dimethyl fumarate	Tecfidera	Probably	Continue / Switch if lymphopaenic	Continue
Low	Natalizumab (EID)	Tysabri	Yes	Continue	Continue or miss infusion depending on timing
Low	Anti-CD20	Ocrelizumab (Ocrevus), Ofatumumab, Rituximab, Ublituximab	Probably	Risk assessment - continue or suspend dosing	Temporary suspension of dosing depending on timing
Intermediate	Cladribine	Mavenclad	Probably	Risk assessment - continue or suspend dosing	Temporary suspension of dosing depending on timing
Intermediate	S1P modulators	Fingolimod (Gilenya), Siponimod (Mazent), Ozanimod, Ponesimod	Probably	Continue	Continue or temporary suspension of dosing
Intermediate	Natalizumab (SID)	Tysabri	Yes	Continue, but consider EID	Continue or miss infusion depending on timing
High*	Mitoxantrone	Novatrone	No	Suspend dosing	Suspend dosing
High*	Alemtuzumab	Lemtrada	No	Suspend dosing	Suspend dosing

High*	H SCT	-	No	Suspend dosing	Suspend dosing
-------	-------	---	----	----------------	----------------

EID - Extended interval dosing; SID - standard interval dosing

Accepted Article